Polycystic Lipomembranous Osteodysplasia with Sclerosing LeukoencephalopathySymptoms, Doctors, Treatments, Advances & More
Learn About Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Jun-ichi Satoh practices practicing medicine in Tokyo, Japan. Mr. Satoh is rated as an Elite expert by MediFind in the treatment of Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy, Subacute Sclerosing Panencephalitis, Schwartz-Jampel Syndrome, and Chondrodystrophy.
Daniela Galimberti practices practicing medicine in Milan, Italy. Ms. Galimberti is rated as a Distinguished expert by MediFind in the treatment of Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy. She is also highly rated in 19 other conditions, according to our data. Her clinical expertise encompasses Frontotemporal Dementia, Dementia, Alzheimer's Disease, and Primary Progressive Aphasia.
Raymond Wang is a Medical Genetics provider practicing medicine in Orange, California. Dr. Wang is rated as an Advanced provider by MediFind in the treatment of Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy. He is also highly rated in 50 other conditions, according to our data. His clinical expertise encompasses Mucopolysaccharidoses (MPS), Mucopolysaccharidosis Type 7 (MPS VII, Sly Syndrome), Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome), Pompe Disease, and Adenoidectomy.
Summary: General aim of the study is the improvement of the clinical knowledge of ultra-rare inherited metabolic and degenerative neurological diseases (prevalence less than 5:100,000) in adulthood through the systematic longitudinal collection of clinical, laboratory and instrumental data.